Changing the Paradigm in HER2-Positive Early Breast Cancer

New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. **Presenters:** **Sara A. Hurvitz, MD, FACP** Professor of Medicine Smith Family Endowed Chair in Women’s Health Senior Vice President, Clinical Research Division Fred Hutch Cancer Center Head, Division of Hematology/Oncology, Department of Medicine University of Washington School of Medicine Seattle, Washington **Shanu Modi, MD** Section Head, HER2 Breast Program Professor and Attending Member Breast Medicine Service, Department of Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Link to full program:  https://bit.ly/4z1Xb6a Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.